Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
March 08 2022 - 4:30PM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced that the Company will present
updated results from its single-agent Phase 1 clinical trial of
RTX-240 in advanced solid tumors in a poster presentation at the
American Association for Cancer Research (AACR) Annual Meeting
being held from April 8-13, 2022 at the Ernest N. Morial Convention
Center in New Orleans, Louisiana. The Company also plans to host a
webcast to discuss the results from the single-agent Phase 1 trial
of RTX-240 in solid tumors and AML on April 8, 2022, at 1:15 p.m.
ET, following the release of the AACR abstracts.
“In March 2021, we reported initial results from the RTX-240
Phase 1/2 clinical trial which established clinical proof of
concept of RTX-240 in advanced solid tumors and clinical validation
of the RED PLATFORM®, unlocking the potential of our entire
oncology platform,” said Pablo J. Cagnoni, M.D., president and
chief executive officer of Rubius Therapeutics. “As part of our
poster at AACR and planned company webcast, we look forward to
presenting updated clinical results from the ongoing RTX-240 trial
in patients with solid tumors and AML, including additional safety,
efficacy and pharmacodynamic data from patients enrolled at higher
dose levels and follow up from the patients who were included in
the March 2021 announcement. We also intend to share our expected
next steps for Phase 2 clinical development.”
Abstract Title: Phase 1 Trial of RTX-240,
Allogeneic Red Blood Cells Engineered to Express 4-1BBL and
Trans-Presented IL-15, in Patients with Advanced Solid
TumorsSession Title: Phase I Clinical Trials
2Session Date and Time: Tuesday, April 12, 2022,
9:00 a.m. – 12:30 p.m. ETLocation: New Orleans
Convention Center, Exhibit Halls D-H, Poster Section
33Poster Board Number: 12Abstract
Number: CT187
Investor WebcastThe Company plans to host a
webcast on April 8, 2022, at 1:15 p.m. ET, following the release of
the AACR abstracts. Details will be available on the Investors
& Media section of the Rubius website.
About RTX-240RTX-240, Rubius Therapeutics’ lead
oncology program, is an allogeneic, off-the-shelf cellular therapy
product candidate that is engineered to simultaneously present
hundreds of thousands of copies of the costimulatory molecule 4-1BB
ligand (4-1BBL) and IL-15TP (trans-presentation of IL-15 on
IL-15Rα) in their native forms. RTX-240 is designed to broadly
stimulate the immune system by activating and expanding both NK and
memory T cells to generate a potent anti-tumor response.
About the RTX-240 Clinical TrialThis is a Phase
1/2 open label, multicenter, multidose, first-in-human
dose-escalation and expansion study designed to determine the
safety and tolerability, pharmacokinetics, maximum tolerated dose
and a recommended Phase 2 dose and dosing regimen of RTX-240 in
adult patients with relapsed/refractory or locally advanced solid
tumors or with relapsed/refractory acute myeloid leukemia. The
trial will also assess the pharmacodynamics of RTX-240 measured by
changes in T and NK cell number and function relative to baseline
and anti-tumor activity. The study will include a monotherapy dose
escalation phase followed by an expansion phase in specified tumor
types during the Phase 2 portion of the trial.
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to biologically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. Rubius Therapeutics was recently named
among the 2021 Top Places to Work in Massachusetts by the Boston
Globe, and its manufacturing site was recently
named 2021 Best Places to Work in Rhode Island by
Providence Business News. For more information, visit
www.rubiustx.com, follow us on Twitter or LinkedIn or like us on
Facebook.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding our
expectations with respect to the potential of our pipeline of Red
Cell Therapeutics, our plans to announce results from our RTX-240
trial in patients with solid tumors and AML and to share expected
next steps for the Phase 2 clinical development, and our
expectations for and beliefs about the initial results from the
RTX-240 trial and its validation of the RED PLATFORM and its impact
on the potential of our entire oncology platform, the extent to
which the COVID-19 pandemic may impact Rubius’ ability to enroll
patients in the trial will depend on future developments and our
expectations regarding our strategy, business plans and focus. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates and
their therapeutic potential, our ability to execute on our plans
and expectations, our analyses of clinical and preclinical data and
other risks identified in our filings with the U.S. Securities
and Exchange Commission (SEC), including our Annual Report on Form
10-K for the year ended December 31, 2021 and subsequent filings
with the SEC, and risks and uncertainties related to the severity
and duration of the impact of COVID-19 on our business and
operations. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
Contacts: InvestorsLori
Murray, Chief Corporate Affairs Officerlori.murray@rubiustx.com
Media Marissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Sep 2023 to Sep 2024